Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia and respiratory-related complications.
The company markets an innovative portfolio of solutions including the TetraGraph® and ExSpiron® 2Xi, for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures. Senzime targets a market opportunity valued more than SEK 40 billion per year and operates with sales teams in the world’s leading markets.